HANGZHOU, China, June 15, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced its financial results for the fiscal year ended March 31, 2023.
Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores, commented, "During the past fiscal year, we continued to provide high-quality services and products to our customers despite the challenging and uncertain market environment. I would like to thank our entire team for their collective efforts and dedication. In the new fiscal year, we are focusing on implementing strategic expansion initiatives to drive our growth including optimizing distribution channels, attracting new customers and enhancing our brand recognition. To further complement our expansion, the continued innovation of our business model and digital transformation remains at the forefront of our business. In addition, we expect to improve our operational efficiency and manage our costs effectively. We remain dedicated to our commitment to creating value for our customers by enriching our product portfolio and providing healthcare services to meet their evolving demand. We believe our concrete advantages in offering diversified product selections, delivering additional value to customers and extending sales network are powerful catalysts for a formidable presence in the healthcare market in the future. We are confident that Jo-Jo Drugstores will keep making a positive impact in China's healthcare market and the communities we serve. We are looking forward to another fruitful fiscal year and we will keep making efforts in generating more value for our shareholders."
Fiscal Year 2023 Financial Highlights
For the Year Ended March 31, | ||||||
($ millions, except per share data) | 2023 | 2022 | % Change | |||
Revenue | 148.81 | 164.39 | (9.5) % | |||
Retail drugstores | 83.35 | 84.23 | (1.0) % | |||
Online pharmacy | 32.39 | 30.22 | 7.2 % | |||
Wholesale | 33.07 | 49.94 | (33.8) % | |||
Gross profit | 34.28 | 36.52 | (6.1) % | |||
Gross margin | 23.0 % | 22.2 % | 0.8pp | |||
Loss from operations | (20.93) | (2.69) | -676.8 % | |||
Net loss | (21.14) | (3.20) | -560.9 % | |||
Loss per share | (2.07) | (0.92) | -125.0 % | |||
*Notes: pp represents percentage points | ||||||
Fiscal Year 2023 Financial Results
Revenue
Revenue for the fiscal year ended March 31, 2023 was $148.81 million, compared to $164.39 million for the same period of last year.
For the Year Ended March 31, | ||||||||||||
2023 | 2022 | |||||||||||
($ millions) | Revenue | Cost of | Gross | Revenue | Cost of | Gross | ||||||
Retail drugstores | 83.35 | 56.55 | 32.2 % | 84.23 | 57.29 | 32.0 % | ||||||
Online pharmacy | 32.39 | 28.51 | 12.0 % | 30.22 | 26.62 | 11.9 % | ||||||
Wholesale | 33.07 | 29.47 | 10.9 % | 49.94 | 43.96 | 12.0 % | ||||||
Total | 148.81 | 114.53 | 23.0 % | 164.39 | 127.87 | 22.2 % | ||||||
Revenue from the retail drugstores business decreased by $0.88 million, or 1.0%, to $83.35 million for the fiscal year ended March 31, 2023, from $84.23 million for the same period of last year. After excluding the impact of exchange rate fluctuation, the actual retail drugstores sales increased by 5.6%. The actual increase in retail drugstore sales was primarily due to continuous efforts in promoting non-National Healthcare Security Administration ("NHSA") covered products, close cooperation with major suppliers, and contribution from the new store sales.
Revenue from the online pharmacy business increased by $2.17 million, or 7.2%, to $32.39 million for the fiscal year ended March 31, 2023, from $30.22 million for the same period of last year. The increase was primarily caused by an increase in sales via e-commerce platforms such as Tmall. The Company maintained a membership care program targeted at chronic disease customers. The Company has closely interacted with members via WeChat by providing healthcare knowledge and reminding customers to refill medicine. By implementing a personalized customer care program, the Company was able to promote sales. Additionally, the Company increasingly cooperates with certain manufacturers to promote their products such as Dendrobium Candidum. These manufacturers reward the Company with lower supply prices and more advertising supports. As a result, the Company is able to better promote sales.
Prescription drugs used to be prohibited from sales online due to safety concern. However, as the government of mainland China has lifted the ban order, online prescription drug sales become popular. As a result, the sale of prescription drugs was $10.61 million in the year ended March 31, 2023, as compared to $10.33 million in the year ended March 31, 2022.
Revenue from the wholesale business decreased by $16.86 million, or 33.8%, to $33.08 million for the fiscal year ended March 31, 2023, from $49.94 million for the same period of last year. As a relatively small wholesale distributor in pharmaceutical products, the Company's sales are subject to significant variance. Wholesale business usually carries low gross profit margin. However, we incurred labor, logistic and tax cost for our wholesale business. As a result, to keep reasonable profitability, we abandoned certain wholesales at low gross profit margin in the year ended March 31, 2023. As a result, the wholesale revenue declined.
Gross profit and gross margin
Total cost of goods sold decreased by $13.34 million, or 10.4%, to $114.53 million for the fiscal year ended March 31, 2023, from $127.87 million for the same period of last year. Gross profit decreased by $2.24 million, or 6.1%, to $34.28 million for the fiscal year ended March 31, 2023 from $36.52 million for the same period of last year. Overall gross margin increased by 0.8 percentage points to 23.0% for the fiscal year ended March 31, 2023, from 22.2% for the same period of last year, due to higher retail drugstores profit margins.
Gross margins for retail drugstores, online pharmacy and wholesale were 32.2%, 12.0%, and 10.9%, respectively, for the fiscal year ended March 31, 2023, compared to gross margins for retail drugstores, online pharmacy and wholesale of 32.0%, 11.9%, and 12.0%, respectively, for the same period of last year.
Loss from operations
Selling expenses decreased by $1.70 million, or 5.5%, to $29.18 million for the fiscal year ended March 31, 2023 from $30.88 million for the same period of last year. The decrease in selling expenses was primarily due to decrease in rent, partially offset by increase in the sales and marketing expenses.
General and administrative expenses increased by $7.48 million, or 91.4%, to $15.67 million for the fiscal year ended March 31, 2023 from $8.19 million for the same period of last year. The increase in general and administrative expenses was primarily due to the increase in bad debt expense. Such expenses as a percentage of revenue increased to 10.5% from 5.0% for the same period a year ago. In the year ended March 31, 2023, the Company recorded an increase in the allowance for bad debts of $7.58 million as compared to the increase in the allowance for bad debts of $1.32 million in the fiscal year ended March 31, 2022.
The Company recorded share based compensation of $10.36 million and $0 for the years ended March 31, 2023 and 2022. In April and December 2022, the Company issued a total of 3,000,000 ordinary shares and recorded share-based compensation of approximately $10.36 million.
The Company recorded an impairment of long-lived assets of $0 and $0.15 million for the year ended March 31, 2023 and 2022. In the year ended March 31, 2023, the Company evaluated the forest land use rights and did not record an impairment. In the year ended March 31, 2022, the Company evaluated the forest land use rights and recorded an impairment of $0.15 million.
Loss from operations was $20.93 million for the fiscal year ended March 31, 2023, compared to $2.69 million for the same period of last year. Operating margin was (14.1)% and (1.6)% for the fiscal year ended March 31, 2023 and 2022, respectively.
Net loss
Net loss was $21.14 million, or $2.07 per basic and diluted share for the fiscal year ended March 31, 2023, compared to net loss of $3.20 million, or $0.92 per basic and diluted share for the same period of last year.
Financial Condition
As of March 31, 2023, the Company had cash of $18.81 million, compared to $18.46 million as of March 31, 2022. Net cash used in operating activities was $3.28 million for the fiscal year ended March 31, 2023, compared to $5.39 million for the same period of last year. The change is primarily attributable to a decrease in cash provided by inventories and biological assets of $2.05 million, a decrease in cash provided by customer deposits of $1.71 million, a decrease in cash due to net loss of $17.94 million offset by an increase of $10.36 million in stock compensation, an increase in cash provided by accounts payable of $5.32 million. Net cash used in investing activities was $0.32 million for the fiscal year ended March 31, 2023, compared to $0.31 million for the same period of last year. The change is primarily attributable to purchases of long term assets. Net cash provided by financing activities was $2.37 million for the fiscal year ended March 31, 2023, compared to $4.84 million for the same period of last year. The change is primarily due to repayment of notes payable and proceeds from equity financing such as private placement and debt financing.
As of March 31, 2023, the Company had a working capital deficit of $2.1 million, a net loss of approximately $21.1 million and net cash used in operating activities of $3.3 million. These factors raise substantial doubt about its ability to continue as a going concern. However, non-cash expenses such as stock-based compensation, bad debt direct write-off and provision, and investment loss accounts for approximately $10.4 million, $7.6 million and $2.3 million respectively. Excluding these non-cash expenses, the net loss is approximately $0.8 million.
In August and October 2022 the Company raised capital by issuing ordinary shares to private investors for a total proceeds of $4.7 million. In January 2023, the Company closed a registered direct offering with gross proceeds of $2.6 million from its effective shelf registration statement.
The Company has a credit line agreement from a local bank as described in detail in Note 16 of its annual report on Form 20-F to be filed the date hereto. As of March 31, 2023, approximately $0.29 million of the aforementioned bank credit line was available for further borrowing. As the economy growth slows down, the national interest continues to decrease. Local banks are encouraged to provide low interest rate loans to local enterprises.
In order to meet its capital demand, the Company may raise funds in the capital market, increase its credit line from the local banks, and improve its store performance in the near future. There can be no assurance that any additional financing will be available on acceptable terms, if at all.
The Company has also obtained additional government insurance reimbursement certificates for its stores opened in the last two years. In a mature store, nearly half of the revenue are generated by customers utilizing the government insurance program. With these certificates, mature stores are able to attract more customers who are eligible for the insurance program, and its sales may significantly increase in the next 12 months.
About China Jo-Jo Drugstores, Inc.
China Jo-Jo Drugstores, Inc. ("Jo-Jo Drugstores" or the "Company"), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services in China. Jo-Jo Drugstores currently operates an online pharmacy and retail drugstores with licensed doctors on site for consultation, examination and treatment of common ailments at scheduled hours. It is also a wholesale distributor of products similar to those carried in its pharmacies. For more information about the Company, please visit http://jiuzhou360.com. The Company routinely posts important information on its website.
Forward-Looking Statements
This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company's encourages you to review other factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission.
For more information, please contact:
Company Contact:
Frank Zhao
Chief Financial Officer
+86-571-88077108
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Tina Xiao
Ascent Investor Relations LLC
+1-917-609-0333
This email address is being protected from spambots. You need JavaScript enabled to view it.
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES | ||||||||
CONSOLIDATED BALANCE SHEETS | ||||||||
March 31, | March 31, | |||||||
2023 | 2022 | |||||||
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
Cash and cash equivalents | $ | 18,807,936 | $ | 18,458,575 | ||||
Restricted cash | 12,762,708 | 16,881,002 | ||||||
Trade accounts receivable | 14,119,606 | 16,736,495 | ||||||
Inventories | 15,309,100 | 16,020,140 | ||||||
Other receivables, net | 2,725,015 | 5,764,660 | ||||||
Advances to suppliers | 142,417 | 571,577 | ||||||
Other current assets | 616,008 | 924,797 | ||||||
Total current assets | 64,482,790 | 75,357,246 | ||||||
OTHER ASSETS | ||||||||
Property and equipment, net | 5,100,264 | 5,922,179 | ||||||
Long-term investment | 1,772,072 | 4,511,539 | ||||||
Farmland assets | 666,721 | 722,283 | ||||||
Long-term deposits | 1,038,125 | 1,761,945 | ||||||
Other noncurrent assets | 790,056 | 822,950 | ||||||
Operating lease right-of-use assets | 13,924,826 | 13,738,081 | ||||||
Intangible assets, net | 3,195,748 | 3,547,986 | ||||||
Total other assets | 26,487,812 | 31,026,963 | ||||||
Total assets | $ | 90,970,602 | $ | 106,384,209 | ||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
CURRENT LIABILITIES | ||||||||
Accounts payable | $ | 26,990,250 | $ | 27,331,381 | ||||
Notes payable | 29,255,776 | 34,189,022 | ||||||
Other payables | 1,314,919 | 2,268,967 | ||||||
Other payables - related parties | 683,560 | 1,561,244 | ||||||
Customer deposits | 695,931 | 1,873,062 | ||||||
Taxes payable | 1,706,909 | 1,381,108 | ||||||
Accrued liabilities | 866,173 | 556,037 | ||||||
Loan payable - current portion | - | 1,957,956 | ||||||
Current portion of operating lease liabilities | 5,131,373 | 3,329,619 | ||||||
Total current liabilities | 66,535,234 | 74,448,396 | ||||||
Long-term operating lease liabilities | 7,768,216 | 9,197,027 | ||||||
Total liabilities | 74,303,450 | 83,645,423 | ||||||
COMMITMENTS AND CONTINGENCIES | ||||||||
SHAREHOLDERS' EQUITY | ||||||||
Ordinary shares; $0.012 par value; 500,000,000 shares authorized; 23,697,210 | 284,367 | 41,752 | ||||||
Preferred shares; $0.001 par value; 10,000,000 shares authorized; nil issued and | - | - | ||||||
Additional paid-in capital | 83,958,418 | 66,516,033 | ||||||
Statutory reserves | 1,309,109 | 1,309,109 | ||||||
Accumulated deficit | (69,273,018) | (48,134,493) | ||||||
Accumulated other comprehensive income | 1,735,135 | 4,352,992 | ||||||
Total shareholders' equity attributed to China Jo-Jo | 18,014,011 | 24,085,393 | ||||||
Noncontrolling interests | (1,346,859) | (1,346,607) | ||||||
Total shareholders' equity | 16,667,152 | 22,738,786 | ||||||
Total liabilities and shareholders' equity | $ | 90,970,602 | $ | 106,384,209 | ||||
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES | ||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||
For the years ended | ||||||||||||
March 31, | ||||||||||||
2023 | 2022 | 2021 | ||||||||||
REVENUES, NET | $ | 148,811,976 | $ | 164,392,555 | $ | 133,134,633 | ||||||
COST OF GOODS SOLD | 114,531,512 | 127,873,515 | 103,890,824 | |||||||||
GROSS PROFIT | 34,280,464 | 36,519,040 | 29,243,809 | |||||||||
SELLING EXPENSES | 29,177,163 | 30,876,959 | 26,954,914 | |||||||||
GENERAL AND ADMINISTRATIVE EXPENSES | 15,668,684 | 8,187,176 | 6,956,029 | |||||||||
STOCK BASED COMPENSATION | 10,360,000 | - | 3,941,600 | |||||||||
IMPAIRMENT OF LONG-LIVED ASSETS | - | 148,795 | 228,506 | |||||||||
TOTAL OPERATING EXPENSES | 55,205,847 | 39,212,930 | 38,081,049 | |||||||||
LOSS FROM OPERATIONS | (20,925,383) | (2,693,890) | (8,837,240) | |||||||||
OTHER INCOME (EXPENSES): | ||||||||||||
INTEREST INCOME | 883,908 | 401,921 | 707,878 | |||||||||
INTEREST EXPENSE | (65,854) | (262,218) | (455,187) | |||||||||
INVESTMENT LOSS | (2,316,994) | - | - | |||||||||
OTHER INCOME (EXPENSES) | 1,680,087 | 455,547 | 176,519 | |||||||||
CHANGE IN FAIR VALUE OF PURCHASE OPTION AND | - | - | 64,090 | |||||||||
LOSS BEFORE INCOME TAXES | (20,744,236) | (2,098,640) | (8,343,940) | |||||||||
PROVISION FOR INCOME TAXES | 394,541 | 1,099,726 | 31,638 | |||||||||
NET LOSS | (21,138,777) | (3,198,366) | (8,375,578) | |||||||||
LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING | (252) | (6,247) | (255,716) | |||||||||
NET LOSS ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, | (21,138,525) | (3,192,119) | (8,119,862) | |||||||||
OTHER COMPREHENSIVE LOSS | ||||||||||||
FOREIGN CURRENCY TRANSLATION ADJUSTMENTS | (2,617,857) | 1,534,807 | 1,377,761 | |||||||||
COMPREHENSIVE LOSS | (23,756,634) | (1,663,559) | (6,997,817) | |||||||||
WEIGHTED AVERAGE NUMBER OF SHARES: | ||||||||||||
Basic | 10,196,552 | 3,479,316 | 3,398,397 | |||||||||
Diluted | 10,196,552 | 3,479,316 | 3,398,397 | |||||||||
LOSS PER SHARES: | ||||||||||||
Basic | $ | (2.07) | $ | (0.92) | $ | (2.39) | ||||||
Diluted | $ | (2.07) | $ | (0.92) | $ | (2.39) | ||||||
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES | ||||||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||||
For the years ended | ||||||||||||
March 31, | ||||||||||||
2023 | 2022 | 2021 | ||||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||||||
Net loss | $ | (21,138,777) | $ | (3,198,366) | $ | (8,375,578) | ||||||
Adjustments to reconcile net loss to net cash used in | ||||||||||||
Bad debt direct write-off and provision | 7,579,886 | 939,720 | (706,862) | |||||||||
Depreciation and amortization | 718,002 | 1,256,491 | 1,750,890 | |||||||||
Impairment of long lived assets | - | 148,795 | 228,506 | |||||||||
Share-based compensation | 10,360,000 | - | 3,941,600 | |||||||||
Investment loss | 2,316,994 | - | - | |||||||||
Change in fair value of purchase option derivative liability | - | - | (64,090) | |||||||||
Change in operating assets and liabilities: | ||||||||||||
Accounts receivable, trade | (2,531,755) | (2,657,283) | (3,307,946) | |||||||||
Notes receivable | (20,861) | 40,260 | 21,539 | |||||||||
Inventories and biological assets | (522,550) | 1,523,098 | (3,615,017) | |||||||||
Other receivables | (958,671) | (1,927,692) | 468,967 | |||||||||
Advances to suppliers | 201,984 | (171,783) | 1,893,857 | |||||||||
Long term deposit | 589,653 | (159,508) | 26,910 | |||||||||
Other current assets | 331,426 | 376,134 | 1,004,448 | |||||||||
Other noncurrent assets | (30,483) | 62,394 | 38,142 | |||||||||
Accounts payable, trade | 1,765,488 | (3,558,050) | 6,380,115 | |||||||||
Other payables and accrued liabilities | (1,341,447) | 99,132 | (183,111) | |||||||||
Customer deposits | (1,035,456) | 678,601 | 368,690 | |||||||||
Taxes payable | 433,054 | 1,162,084 | 66,648 | |||||||||
Net cash used in operating activities | (3,283,513) | (5,385,972) | (62,292) | |||||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||||||
Disposal of financial assets available for sale | - | - | 75,973 | |||||||||
Acquisition of equipment and building | (118,272) | (89,960) | (126,766) | |||||||||
Investment in a joint venture | (4,379) | - | (1,470,119) | |||||||||
Purchases of intangible assets | (12,774) | (7,012) | (97,802) | |||||||||
Additions to leasehold improvements | (180,672) | (209,166) | (379,611) | |||||||||
Net cash used in investing activities | (316,097) | (306,138) | (1,998,325) | |||||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||||||
Proceeds from short-term bank loan | - | - | 738,315 | |||||||||
Repayment of short-term bank loan | - | (779,059) | (1,476,630) | |||||||||
Proceeds from third parties loan | - | - | - | |||||||||
Repayment of third parties loan | (1,811,558) | (2,613,965) | (2,395,629) | |||||||||
Proceeds from notes payable | 57,965,013 | 65,370,181 | 48,292,231 | |||||||||
Repayment of notes payable | (60,273,598) | (57,829,269) | (51,295,776) | |||||||||
Increase in financial liability | - | - | (73,832) | |||||||||
Exercise of warrants | - | - | 77,500 | |||||||||
Proceeds from issuance of shares and warrants in private | 7,325,000 | - | 9,287,100 | |||||||||
Proceeds from other payable-related parties | 43,785 | 689,010 | - | |||||||||
Repayment of other payable-related parties | (882,486) | (73,426) | ||||||||||
Net cash provided by financing activities | 2,366,156 | 4,836,898 | 3,079,853 | |||||||||
EFFECT OF EXCHANGE RATE ON CASH | (2,535,479) | 1,522,146 | 2,670,802 | |||||||||
INCREASE IN CASH AND CASH EQUIVALENTS AND | (3,768,933) | 666,933 | 3,690,038 | |||||||||
CASH AND CASH EQUIVALENTS AND RESTRICTED | 35,339,577 | 34,672,644 | 30,982,606 | |||||||||
CASH AND CASH EQUIVALENTS AND RESTRICTED | $ | 31,570,644 | $ | 35,339,577 | $ | 34,672,644 | ||||||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW | ||||||||||||
Cash paid for income taxes | $ | 64,943 | $ | 3,955 | $ | 37,738 | ||||||
Cash paid for interest | 63,668 | 262,218 | 455,187 | |||||||||
NON-CASH ACTIVITIES: | ||||||||||||
Cashless exercise of warrants | $ | 135,118 | $ | - | $ | - | ||||||
| Last Trade: | US$1.85 |
| Daily Change: | -0.18 -8.87 |
| Daily Volume: | 3,514 |
| Market Cap: | US$12.300M |
September 26, 2023 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
